Pure Global
NCT05841797

Evaluation of Problem Management Plus in Pregnant Women With HIV in Kenya

Piloting Risk Stratification and Tailored Interventions With Pregnant and Postpartum Women With HIV in Kenya to Prevent Disengagement From Care and Viral Failure
University of Colorado, Denver·ClinicalTrials.gov·behavioralNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Human Immunodeficiency Virus
Drug/Device/Intervention
In-Person Program Management Plus (PM+)
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
University of Colorado, Denver
Location
Nairobi, Kenya
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2024
End date
Aug 31, 2025
Enrollment
120 participants
Primary outcome

Change in the combined retention and treatment failure outcome

Summary

This study includes secondary quantitative analysis, qualitative methods, and hybrid type 2
 implementation-effectiveness pilot trial. The overall goal of this protocol is to determine
 whether risk stratification of PWLWH in conjunction with a tailored psychosocial support
 intervention can optimize health outcomes for the vulnerable women and infants. This study
 will be conducted in high-volume, low-resource health facilities in Kisumu County, Kenya,
 which is a priority area for research among WLWH and one of the highest HIV burden counties.

ICD-10 classifications
Human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other conditionsHuman immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesAsymptomatic human immunodeficiency virus [HIV] infection status
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05841797
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05841797 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Colorado, Denver and is currently Not yet recruiting. The study focuses on Human Immunodeficiency Virus. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.